NRC Form 374
(3-83)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 5

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter 1, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

1. Honolulu Medical Group

2. 550 South Beretania Street
Honolulu, Hawaii 96813

3. License number 53-16421-01

4. Expiration date April 30, 1991

5. Docket or Reference No. 030-11006

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed
D. Any byproduct material identified in 10 CFR 35.500	D. Sealed sources for diagnostic devices	D. 800 millicuries per source
E. Any byproduct material identified in 10 CFR 31.11	E. Prepackaged Kits	E. As needed

9. Authorized use:

A. Medical use described in 10 CFR 35.100.
B. Medical use described in 10 CFR 35.200.
C. Medical use described in 10 CFR 35.300.
D. Medical use described in 10 CFR 35.500.
E. In vitro studies.

1/1 MC50

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
53-16421-01

Docket or Reference number
030-11006

Amendment No. 5

CONDITIONS

10. Location of use: 550 South Beretania Street; Honolulu, Hawaii

11. Radiation Safety Officer: Richard L. Littenberg, M.D.

12. Authorized users:

    A. Richard L. Littenberg, M.D. for materials identified in 10 CFR 35.100, 35.200, 35.300, 35.500, 31.11.

13. No single patient administration for treatment of thyroid carcinoma shall exceed 30 millicuries.

14. The licensee may use the Calicheck device for doing linearity tests of its dose calibrator provided it follows the procedures in the Calcorp, Inc. Manual dated March 2, 1982.

15. This license is based on the licensee's statements and representations in the following documents:

    A. Application dated February 15, 1980
    B. Letter dated November 13, 1980
    C. Letter received March 23, 1981
    D. Application dated February 26, 1986
    E. Letter dated April 4, 1986
    F. Letter dated June 18, 1987

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date August 13, 1987

By original signed by B. A. Riedlinger

Beth A. Riedlinger
Health Physicist (Licensing)
Nuclear Materials Safety Section
Region V